A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Summary

To demonstrate the efficacy of SHR-1314 at Week 12 in subjects with proliferation lupus nephritis in terms of improvement of 24h UPCR, compared to placebo. The study will also assess the safety and tolerability of SHR-1314 in the patient population over the study period.

Timeline

Start

2021-06-28

Primary completion

2021-12-25

Completion

2022-09-03

Drugs

Indications